Recent studies also demonstrated that anti-inflammatory compounds, which inhibit NF-κB activation, prevent the development of atherosclerosis, without lowering serum lipid levels, in hyperlipidemic mice [4, 27]. This evidence concerns the gene NFKB1 and atherosclerosis.